Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases만성 폐질환 환자에서 BNT162b2 COVID-19 백신 2회 접종 후 손상된 면역학적 결과와 관련된 항체 반응 및 위험 인자Article Published on 2022-07-012022-09-12 Journal: BMJ Open Respiratory Research [Category] MERS, 진단, [키워드] 1:1 1.26 95% CI adjusted antibody concentration Antibody Response aRR association Asthma bronchiectasis Charlson Comorbidity Index chronic pulmonary disease cohort study Comorbidity Control controls copd epidemiology COVID-19 COVID-19 vaccination COVID-19 vaccine defined dose Factor fibrosis first vaccination functional geometric healthcare personnel Humoral response identify immunological immunological responses Immunosuppression immunosuppressive Inclusion increasing age Interaction interstitial interstitial fibrosis. lowest mRNA neutralising neutralising antibody of BNT162b2 outcome Patient Poisson regression Prednisolone Primary outcome Prospective quartile Receptor binding domain reported Responder response responses risk risk factor secondary outcome tested vaccination [DOI] 10.1136/bmjresp-2022-001268 PMC 바로가기 [Article Type] Article
Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity스파이크 단백질에 대한 항체 결합 통계는 항체 농도 및 친화도에 대한 COVID 19 감염 위험의 의존성을 설명합니다Article Published on 2022-06-072022-09-12 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] antibody Antibody binding antibody concentration binding binding domain Blood Breakthrough infection can be used Concentration COVID 19 COVID-19 Critical decrease distribution Efficacy explain IgG Immunity induce Infection infection risk Probability required risk risk of infection SARS-CoV-2 vaccine Spike protein Statistics the spike protein vaccination Vaccine Variation virus [DOI] 10.1038/s41598-022-13748-3 PMC 바로가기 [Article Type] Article
Humoral response to SARS-CoV-2 vaccines in people living with HIVHIV 감염자의 SARS-CoV-2 백신에 대한 체액 반응Article Published on 2022-06-012022-09-12 Journal: Infection [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] adjusted Analysis anti-SARS-CoV-2 antibody anti-SARS-CoV-2-antibody antibody antibody concentration Antibody Response association CD4 CD4 cell comparative statistics Concentration concentrations COVID-19 COVID-19 vaccine COVID-19 vaccines cumulative electronic patient file Factor female Generalized Germany HIV humoral immune response Humoral response identify IQR Linear model logit magnitude males median mRNA vaccine Munich PLWH quartiles robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2. significantly subjects threshold vaccination variable were used with HIV [DOI] 10.1007/s15010-021-01721-7 PMC 바로가기 [Article Type] Article
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies림프성 악성종양 환자에서 BNT162b2 mRNA 백신 2회 및 3회 투여 후 항-SARS-CoV-2 항체 반응Article Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] affected anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD38 anti-RBD Anti-RBD IgG antibody antibody concentration Antibody concentrations Antibody Response B-cell malignancies B-cell malignancy benefit binding domain booster Cell Cohort Concentration conducted Course COVID-19 COVID-19 patient COVID-19 patients disorders dose effective evaluate haematological malignancies haematological malignancy Haematologicalmalignancies humoral Humoral response humoral responses IgG Immunocompromised increment IQR lymphoid lymphomas malignancies malignancy median monoclonal Mortality mRNA vaccination mRNA vaccine of BNT162b2 Patient patients patients treated plasma Plasma cell Prophylaxis quantification RBD SARS-CoV-2 Seroconversion seroconversion rate seroconverted serological serological response serology significantly spike the disease the vaccine therapy third dose Vaccine vaccine dose vaccine. [DOI] 10.1016/j.cmi.2022.02.029 PMC 바로가기 [Article Type] Article
Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare ProfessionalsBNT162b2 1차, 2차, 3차 접종 후 SARS-CoV-2 특이 항체 반응의 차이Observational Study Published on 2022-05-272022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료법, [키워드] addition age analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody anti-S anti-S antibody anti-S antibody dynamics Anti-spike antibody concentration BMI BNT162b2 BNT162b2 vaccine booster Concentration concentrations COVID-19 Critical determine difference different time point dose doses effective vaccine Effective vaccines first dose hcp healthcare Healthcare professional healthcare professionals humoral immune response humoral immune response. humoral immune responses immune responses increase in individual infected individual infected individuals Infection median median value naïve naïve individual naïve individuals of BNT162b2 omicron predictor professional Protective response Safe SARS-CoV-2 second second dose sera Sex significant difference significant differences significantly Spread statistically steadily decreased systemic adverse event systemic adverse events vaccination vaccination schedule Vaccine variant variants of SARS-CoV-2 were used [DOI] 10.3389/fimmu.2022.876533 PMC 바로가기 [Article Type] Observational Study
Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2미세유체 항체 친화성 프로파일링은 SARS-CoV-2에 대한 방어에서 기억 재활성화 및 교차 반응성의 역할을 보여줍니다Article Published on 2022-04-082022-09-12 Journal: ACS Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute SARS-CoV-2 infection ADE adverse effect affinity Against antibody antibody affinity antibody concentration antibody profiling Antibody-dependent enhancement Antigen Concentration convalescent coronavirus Course COVID-19 COVID-19 convalescent patient COVID-19 patient cross-reactive antibodies cross-reactive antibody cross-reactivity Determining detrimental effect effort ELISAs endemic human coronavirus enzyme-linked immunosorbent assay evaluate HCoV-HKU1 HCoV-NL63 humoral immune response Immunity Infection memory memory B-cell memory immunity microfluidics. new SARS-CoV-2 nine parameter Pathogens Profiling Reactivation recent role SARS-CoV-2 SARS-COV-2 infection sequence similarity sera seropositive severity Spike protein the SARS-CoV-2 [DOI] 10.1021/acsinfecdis.1c00486 PMC 바로가기 [Article Type] Article
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab인플릭시맙과 베돌리주맙으로 치료받은 염증성 장질환 환자에서 SARS-CoV-2 백신 2회 투여 후 항체 붕괴, T 세포 면역 및 돌발성 감염Article Published on 2022-03-162022-09-11 Journal: Nature Communications [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] anti-S anti-TNF antibody antibody concentration BNT162b2 Breakthrough infection breakthrough infections ChAdOx1 ChAdOx1 nCoV-19 Concentration dose drug geometric mean half-live immune responses Immunity impair induce Inflammatory bowel disease infliximab Influenza influenza vaccination integrin nCoV Necrosis of BNT162b2 p value Patient patients patients treated pneumococcal predicted protective immunity RBD required respiratory respiratory infection risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine sustained T cell T cell response treated treatment groups tumour necrosis factor U/mL vaccination vaccination schedule vaccine doses vaccine-induced immune response vedolizumab [DOI] 10.1038/s41467-022-28517-z PMC 바로가기 [Article Type] Article
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy항-CD20 치료 이력이 있는 환자에서 체액성 및 세포성 면역의 궤적과 SARS-CoV-2에 대한 3차 mRNA 백신에 대한 반응Article Published on 2022-03-012022-09-11 Journal: RMD Open [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] Analysis anti-CD20 anti-CD20 therapy anti-CD20 treatment anti-SARS-CoV-2 immune response anti-SARS-CoV-2 immune responses antibody concentration Antibody concentrations cell-mediated immune Cell-mediated immunity cellular immunity CMI comparable Concentration Control covariance COVID-19 decay dose elicited healthy volunteer healthy volunteers humoral humoral and cell-mediated immunity Humoral response humoral responses IgG immune responses Immunity immunogenicity inefficient interferon interferon-γ investigated Linear regression majority mRNA vaccine non-responder non-responders outcome Participants Patient patients registration number Responder responders response reveal rituximab RNA SARS-CoV-2 SARS-CoV-2 vaccine second vaccination systemic vasculitis Therapies therapy Trajectories trajectory Trial Registration Number vaccination Vaccination strategy vaccination. Vaccine vaccine dose Vasculitis [DOI] 10.1136/rmdopen-2021-002166 PMC 바로가기 [Article Type] Article
Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2SARS-CoV-2에 노출되거나 노출되지 않은 의료 종사자의 시간 경과에 따른 BBIBP-CorV 백신에 대한 체액 반응Clinical Trial Published on 2022-03-012022-09-12 Journal: Molecular immunology [Category] MERS, SARS, 임상, 진단, [키워드] age Analysis analyzed anti-spike antibodies anti-Spike IgG antibody antibody concentration Antibody Response Antibody titer BBIBP-CorV both group Combination dose event healthcare worker highest humoral Humoral response immune protection increase in individual Linear regression model magnitude memory B multivariable naïve subject participant persistence produced SARS-CoV-2 SARS-CoV-2 infected individual SARS-COV-2 infection SARS-CoV-2 infection. second dose sequence significant increase significantly significantly higher single dose Sinopharm subject subjects T cell responses the vaccine vaccination Vaccine women younger subject [DOI] 10.1016/j.molimm.2022.01.009 PMC 바로가기 [Article Type] Clinical Trial
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy Research Published on 2022-02-282022-10-05 Journal: NPJ Vaccines [Category] 임상, 치료기술, 치료법, [키워드] ACE2 activity age anti-RBD antibody concentration antiretroviral Antiretroviral therapy assessment benefit CD4+ T-cell ChAdOx1 characterized chronic health conditions circulating antibody co-morbidities controls correlation COVID-19 vaccination COVID-19 vaccine domain dose doses Factor Health healthy HIV HIV infection humoral Humoral response immune response initial IQR magnitude median multivariable new SARS-CoV-2 Older age PLWH ranged RBD receiving response second dose significantly Sociodemographic Spike protein the SARS-CoV-2 Treatment vaccination Vaccine vaccine dose vaccine doses variables variant Viral load viral neutralization with HIV [DOI] 10.1038/s41541-022-00452-6 [Article Type] Research